BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27824660)

  • 1. Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years.
    Flannelly GM; Mooney MT; Greehy GM; Keogh EB; McNally SA; Fitzpatrick PE
    Eur J Cancer Prev; 2018 Mar; 27(2):158-163. PubMed ID: 27824660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
    Luyten A; Buttmann-Schweiger N; Luyten K; Mauritz C; Reinecke-Lüthge A; Pietralla M; Meijer CJ; Petry KU
    Int J Cancer; 2014 Sep; 135(6):1408-16. PubMed ID: 24519782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.